Sanofi $SNY Stock: Equity Investment Corp Grows Holdings

Equity Investment Corp lifted its stake in Sanofi (NASDAQ:SNY) by 1.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,636,859 shares of the company’s stock after buying an additional 34,888 shares during the period. Sanofi makes up approximately 1.5% of Equity Investment Corp’s investment portfolio, making the stock its 23rd biggest position. Equity Investment Corp owned about 0.11% of Sanofi worth $108,718,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC grew its holdings in shares of Sanofi by 12.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 26,523 shares of the company’s stock worth $1,054,000 after purchasing an additional 2,968 shares in the last quarter. Almanack Investment Partners LLC. acquired a new position in Sanofi in the third quarter valued at about $273,000. Euro Pacific Asset Management LLC raised its stake in Sanofi by 0.6% in the third quarter. Euro Pacific Asset Management LLC now owns 46,121 shares of the company’s stock valued at $1,902,000 after purchasing an additional 253 shares in the last quarter. M Holdings Securities Inc. raised its stake in Sanofi by 4.1% in the third quarter. M Holdings Securities Inc. now owns 21,716 shares of the company’s stock valued at $989,000 after purchasing an additional 853 shares in the last quarter. Finally, Ethic Inc. lifted its position in Sanofi by 12.6% during the third quarter. Ethic Inc. now owns 145,079 shares of the company’s stock worth $5,982,000 after purchasing an additional 16,290 shares during the period. Institutional investors and hedge funds own 14.03% of the company’s stock.

Sanofi Stock Up 0.2%

Shares of NASDAQ SNY opened at $48.23 on Wednesday. The company has a market cap of $116.93 billion, a price-to-earnings ratio of 23.88, a PEG ratio of 1.32 and a beta of 0.31. The company has a current ratio of 1.12, a quick ratio of 0.27 and a debt-to-equity ratio of 0.20. Sanofi has a 12 month low of $39.07 and a 12 month high of $52.68. The stock has a 50-day moving average price of $42.44 and a two-hundred day moving average price of $44.36.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Friday, October 30th. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.56 by $0.48. The company had revenue of $17.25 billion for the quarter, compared to the consensus estimate of $14.30 billion. Sanofi had a net margin of 8.70% and a return on equity of 15.16%. The firm’s quarterly revenue was up 16.2% compared to the same quarter last year. During the same period last year, the company posted $2.91 EPS. As a group, analysts forecast that Sanofi will post 5.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on SNY. Wolfe Research began coverage on shares of Sanofi in a research note on Friday, October 9th. They set a “peer perform” rating on the stock. Berenberg Bank restated a “buy” rating on shares of Sanofi in a research report on Monday, October 5th. Wall Street Zen upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a report on Thursday, October 1st. Finally, Royal Bank Of Canada began coverage on shares of Sanofi in a research report on Tuesday, September 8th. They set a “sector perform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and twelve have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $53.00.

About Sanofi

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.